LAUSANNE, Switzerland and IRVINE, California, April 18 /PRNewswire-FirstCall/ -- IsoTis S.A. will release its first quarter 2006 results on April 27 before the financial markets open. To discuss these results, the Company will conduct a conference call at 4.30 p.m. CET/10.30 a.m. ET/7:30 a.m. PT.
The call will be audiocast live on the IsoTis website at www.isotis.com (- investors - IR investor center). To participate in the conference call, dial: +41 91 610 5609 (Europe); +44 20 7107 0613 (UK); +1 866 865 5144 (toll free dial in US/Canada); no password required. Digital playback is available for 24 hours after the conference starting at 6.00 p.m. until February 28, 6.00 p.m. CET, dial: +41 91 612 4330 (Europe); +44 20 7108 6233 (UK); +1 866 416 2558 (US/Canada); Conference ID: 019#. The audiocast will remain available on IsoTis’ website at least through June 30, 2006.
The Company completed the timely filing of its annual report on Form 20-F with the U.S. Securities and Exchange Commission (“SEC”). IsoTis’ Form 20-F is accessible through the company’s website (-investors - IR investor center - SEC filings) or through the SEC website (www.sec.gov).
About the company:
IsoTis OrthoBiologics has a product portfolio with several innovative and proprietary natural and synthetic bone graft substitutes on the market and others in development, an established North American independent distribution network, and an expanding international presence. The company’s main commercial operations are based out of Irvine, CA; its international sales headquarters is based in Lausanne, Switzerland.
IsoTis OrthoBiologics
CONTACT: Hans Herklots, Director IR Rob Morocco, CFO, Tel:+41(0)21-620-6011 +1-949-855-7158, E-mail: hans.herklots@isotis.com,robert.morocco@isotis.com
